Liminatus Pharma, Inc. (LIMN)
NGM · Healthcare · Biotechnology
$0.12
-10.29%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$5.5M
Shares Outstanding
44.9M
P/S (TTM)
nanx
Exchange
NGM
Currency
USD
About Liminatus Pharma, Inc.
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | |
| Operating Income | -701K | -884K | -1.1M | |
| Net Income | -1.8M | -8.2M | -1.1M | |
| Diluted EPS | $nan | $-0.07 | $nan | $-0.03 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.7M | -4.8M | -3.3M | -3.0M |
| Net Income | -2.9M | -5.0M | -3.5M | -10.2M |
| Diluted EPS | $-0.11 | $-0.19 | $-0.14 | $-0.43 |